Zymetech
Zymetech is a private Icelandic biotech company founded in 1999, specializing in research, development, production, and sales of marine-derived enzymes for therapeutic applications, headquartered in Reykjavík with 11-50 employees.
- Company typePrivate
- Founded1999
- HeadquartersReykjavík, Iceland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Zymetech does
Zymetech is a private Icelandic biotechnology company headquartered in Reykjavík, founded in 1999. The company specializes in the research, development, production, and sales of marine-derived enzymes for therapeutic applications, positioning itself as a globally focused player in a niche segment of enzyme-based therapeutics derived from marine biological sources.
The firm operates with 11-50 employees according to available firmographic data, indicating a small to mid-sized specialty biotech. Zymetech has historically secured non-dilutive or grant-style funding from Iceland's Technology Development Fund, with five disclosed rounds between 2009 and 2015 totaling approximately $873,887. This funding pattern is consistent with a research-intensive, pre-commercial or early-commercial stage company reliant on public innovation financing rather than venture capital.
A significant data integrity caveat applies to this analysis: the aggregated source material contains extensive operational detail about Enzymatica AB, a separately incorporated Swedish company (Lund-based, First North Growth Market-listed under ticker ENZY) that develops a barrier technology cold-prevention spray called ColdZyme. These Enzymatica-specific facts — including its product portfolio, STADA distribution partnership, University of Kent research collaborations, and public market listing — do not pertain to Zymetech and have been excluded from Zymetech's profile. No Zymetech-specific revenue, customer, pricing, or go-to-market data is available in the provided sources.
Zymetech firmographics
Firmographics- Name
- Zymetech
- Website
- https://zymetech.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Zymetech is a private Icelandic biotech company founded in 1999, specializing in research, development, production, and sales of marine-derived enzymes for therapeutic applications, headquartered in Reykjavík with 11-50 employees.
- Ownership category
- akta.pro rank
Zymetech industry classification
Industry- Product category
- Therapeutic enzymes
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Dairy & Cheese Processing Enzymes (AFAJAIAB)
- akta.pro secondary industry
- Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins) (AFAJAHAL)
Keywords
Where Zymetech is headquartered
LocationHeadquarters
- HQ city
- Reykjavík
- HQ country
- Iceland
- HQ region
- Europe
Offices1 record
Markets served
Zymetech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Zymetech product offering
Product offeringCore offering
Zymetech is a globally leading company engaged in the research, development, production, and sales of marine-derived enzymes for therapeutic application. Founded in 1999 in Reykjavík, Iceland, the firm produces enzymes sourced from marine organisms that are used as therapeutic inputs. The company operates as a small specialized manufacturer (11-50 employees) and has historically been funded in part through Icelandic Technology Development Fund grants.
Product overview
Enzymatica offers a platform-based product portfolio centered on its barrier technology platform and the core ColdZyme mouth spray product. The barrier technology platform enables the development of enzymatic formulations that create protective barriers against viruses and microorganisms. ColdZyme is the primary consumer-facing product utilizing this technology, delivered as a mouth spray for cold prevention and symptom relief.
Differentiator
Problem solved
Functional benefit
Products and services
- Marine-derived therapeutic enzymes
Quantifiable outcome
- ColdZyme reduces cold duration and symptoms - validated by independent study in Journal of Physiology
- +1 more outcomes
Companies that use Zymetech
Customer profileSegments1 record
Ideal customer profiles1 record
Zymetech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Zymetech partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- Unibet Rose RocketsminorSports sponsorship partnership for Giro d'Italia cycling race to increase brand visibility and marketing reach for ColdZyme products.
- STADAcoreInternational distribution partnership with STADA for ColdZyme products. STADA is a major pharmaceutical company that distributes Enzymatica's products in international markets outside the Nordic region.
- University of KentcoreAcademic research partner in independent clinical studies on ColdZyme effectiveness. Collaborated on peer-reviewed research published in Journal of Physiology.
- Ignaz Semmelweis-institutet and Vetmeduni WiencoreResearch partners in independent studies on ColdZyme. Joint research published in Journal of Physiology confirming the product reduces cold duration and symptoms.
Scale indicators2 records
Recent moves4 records
Expansion highlights1 record
Zymetech competitors and assessment
Company assessmentDirect peers
- Enzymatica AB: Swedish enzyme-based therapeutics company (ColdZyme mouth spray) that, like Zymetech, develops enzyme-based products targeting human health. Both operate at the intersection of proprietary enzyme platforms and consumer/therapeutic health applications, though Enzymatica is publicly listed.
- Marinomed Biotech AG: Austrian biopharmaceutical company specializing in marine-derived therapeutics (e.g., iota-carrageenan-based products). Most directly comparable peer: builds therapeutic products from marine-sourced compounds, mirroring Zymetech's marine-therapeutic positioning.
Regional players
- LYSI hf: Icelandic marine ingredients company producing fish oils and marine-derived health ingredients. Comparable via shared Icelandic origin and marine bioresource sourcing, though LYSI focuses on oils rather than therapeutic enzymes.
Broad incumbents
- Aker BioMarine: Norwegian marine biotech company harvesting krill and other marine resources for health and nutrition markets. Comparable via marine-sourced bioactive compounds and therapeutic/nutraceutical applications, though at much greater scale.
- Novonesis (formerly Novozymes): Global enzyme powerhouse with extensive therapeutic and industrial enzyme portfolio. Comparable as the dominant commercial enzyme player; Zymetech competes in a niche within this broader market.
- AB Enzymes: Specialty enzyme manufacturer serving food, feed, and industrial applications. Comparable as a specialty enzyme producer, though AB Enzymes is broader in scope and much larger than Zymetech.
Emerging players
- Biocatalysts Ltd: UK-based specialist enzyme developer producing bespoke enzymes for food, pharma, and industrial customers. Comparable as a smaller specialty enzyme company developing niche enzyme products, similar in scale and positioning to Zymetech.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat1 record
Key risks6 records
Key highlights5 records
Customer concentration
Zymetech social profiles
Digital presenceZymetech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Zymetech leadership team
Management profileNumber of profiles
Profiles1 record
Zymetech funding detail
Funding detailFunding overview
Funding rounds5 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Zymetech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Zymetech
What does Zymetech do?
Zymetech is a globally leading company engaged in the research, development, production, and sales of marine-derived enzymes for therapeutic application. Founded in 1999 in Reykjavík, Iceland, the firm produces enzymes sourced from marine organisms that are used as therapeutic inputs. The company operates as a small specialized manufacturer (11-50 employees) and has historically been funded in part through Icelandic Technology Development Fund grants.
When was Zymetech founded?
Zymetech was founded in 1999. It employs 11 to 50 people.
Where is Zymetech based?
Zymetech is headquartered in Reykjavík, Iceland, in the Europe region.
Who are Zymetech's main competitors?
Direct peers on record are Enzymatica AB and Marinomed Biotech AG. LYSI hf is listed as a regional player. Broad incumbents are Aker BioMarine, Novonesis (formerly Novozymes) and AB Enzymes. Biocatalysts Ltd is listed as an emerging player.
Does Zymetech have an API?
No public API is recorded for Zymetech.
What industry is Zymetech in?
Zymetech's product category is Therapeutic enzymes. Its primary akta.pro industry code is AFAJAIAB, Dairy & Cheese Processing Enzymes, with a secondary code of AFAJAHAL, Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins). Its NAICS code is 325412 and its SIC code is 2833.